MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...
MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
CROWN POINT | The mental state of a Gary man convicted of shooting a close friend to death dominated his sentencing hearing Monday, as it had his trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback